Resistance to etoposide has been associated with the overexpression of P-glycoprotein and MRP1 in human tumor cells. However, the role of BCRP in resistance to etoposide has not been clearly established, especially the significance of arginine 482 mutations in drug transport (cellular uptake and efflux). Different levels of resistance to etoposide have been recently observed in cells expressing BCRP in terms of cytotoxicity. The aim of this work was to study the effects of these mutations on the functional involvement of BCRP in etoposide transport. HEK293 cells were transfected with an empty vector (HEK/V), the vector bearing the wild-type BCRP (HEK/R482), the mutant arginine-482-glycine (HEK/R482G) or the mutant arginine-482-threonine (HEK/R482T). MTT assay was used to study the cytotoxic effect of etoposide and 3 H]-etoposide uptake in BCRP-transfected cells and especially in HEK/R482G ones. Our data show that the R482G mutation in BCRP is able to increase efflux of etoposide and that mutation analysis at codon 482 may be of clinical importance in cancers treated with etoposide.
Introduction
One of the mechanisms of resistance to anticancer chemotherapy has been linked to the overexpression of ABC membrane transporters leading to the decrease of the intracellular drug concentration. These proteins include P-glycoprotein/MDR1 (ABCB1) (1), multidrug resistanceassociated protein/MRP (ABCC) (2) and the ABC half transporter breast cancer resistance protein/BCRP (ABCG2) (3, 4) .
Resistance to etoposide has been mainly associated with the overexpression of P-glycoprotein and MRP1 (1, 2) . Different levels of resistance to etoposide have been recently observed in cells expressing BCRP (5, 6) . Murine cells selected for resistance to doxorubicin that overexpress the mouse Bcrp1 gene were also resistant to etoposide (7) . Moreover, the reduced cellular accumulation and resistance to etoposide in cells lacking P-glycoprotein (P-gp) and Mrp1 proteins have been related to the overexpression and/or amplification of the Bcrp1 gene (8) .
Human BCRP gene was initially identified in resistant breast carcinoma cells selected for resistance to doxorubicin and verapamil. In these cells the BCRP gene has been shown to be mutated in the exon 5 leading to the substitution of the arginine 482 for a threonine (R482T). The same amino acid is also mutated in another cell line but substituted for a glycine (R482G) (9, 10) . The affinity of BCRP to several substrates has also been found altered by the mutation arginine 482 (9, 11) .
Nevertheless, although the role of BCRP in etoposide resistance is well established in murine cells, its functional involvement in human in terms of drug transport (cellular uptake and efflux), as well as the significance of arginine 482 mutations has not been investigated. We studied the resistance to etoposide and its cellular transport in HEK293 cells transfected by the human wild-type BCRP or its R482G and R482T mutants. We show that cells expressing the R482G mutant display higher resistance level to etoposide than the wild-type BCRP or the mutant R482T genes. (12) . Cells were grown as monolayer in MEM (Invitrogen, Paris, France) supplemented with 10% fetal calf serum and 100 µg/ml penicillin, and 100 µg/ml streptomycin. The human ovarian carcinoma subline 2008/MRP1 which is stably transfected with MRP1 cDNAs and their parental cells 2008 were kindly provided by Professor P. Borst (13) . The 2008 cell lines were cultured in the RPMI-1640 (Invitrogen) supplemented with 10% fetal calf serum, 100 µg/ml penicillin and 100 µg/ml streptomycin. mRNA analysis. RNA was extracted from 5x10 6 cells using the RNAeasy mini kit and DNAse I (Qiagen, Paris, France) according to the manufacturer's instructions. Total RNA (1 µg) was reverse transcribed using random hexamers, MMLV reverse transcriptase and reaction buffer provided in the Superscript First-Strand Synthesis System kit (Invitrogen). Real-time quantification was performed on the ABI Prism 7000 Sequence Detection System (Applied Biosystems, Foster City, USA) using 5 µl of diluted cDNA, 350 nM of forward and reverse primers and SYBR-Green PCR Master Mix in a 25-µl reaction volume under following conditions: 95˚C for 10 min, followed by 40 cycles of 94˚C for 45 sec, 60˚C for 45 sec, 72˚C for 45 sec and finally 72˚C for 10 min. Primers for BCRP (forward 5'-CAGGTCTGTTTCAATCTCACA-3' and reverse 5'-TCCATATGGTGGAATGCTGAAG-3') and MRP1 (forward 5'-GAAGGCCATCGGACTCTTCA-3' and reverse CAGCGCGGACACATGGT) were designed using the Primer Express software (Applied Biosystems). Primers for TBP (forward 5'-GCACAGGAGCCAAGAGTGAA-3' reverse 5'-TCACAGCTCCCCACCATGTT-3') were used according to (14) . Quantification of TBP as an endogenous control gene was performed to standardize the amount of cDNA added to each reaction. Data are presented as relative expression of BCRP or MRP1 using the comparative threshold cycle (Ct) method. (Table II) .
Materials and methods

Drugs
Cytotoxic effects of mitoxantrone and etoposide. The cytotoxic effect of etoposide has been determined in BCRP-transfected cells and in control HEK/V cells. As control, experiments have also been performed using the well-known BCRP substrate, mitoxantrone (16) and 2008/MRP1 cell line as a positive control for etoposide resistance (17) (Fig. 2 and Table III) .
Results indicate that the expression of wt BCRP (HEK/ R482) confers 5-fold resistance to etoposide, as compared to parental cells (HEK/V). Interestingly, the resistance factor was significantly increased to 30-fold in the glycine mutant (HEK/R482G). In contrast, resistance to etoposide in HEK/ R482T cell line remains in the same range of HEK/R482 cell line. For mitoxantrone, the resistance observed was not significantly different between HEK/R482 cell line and the two mutants and was ranging between 11-to 20-fold ( Fig. 3 and Table III ). The resistance to mitoxantrone and etoposide in HEK/ R482 cells was modulated by the BCRP inhibitors novobiocin (18, 19) and FTC (20) (Table III) . However, novobiocin was able to modulate resistance to etoposide to a lesser extent than FTC. By contrast, FTC was able to reverse resistance to etoposide moderately in HEK/R482G cell line as compared to novobiocin. Novobiocin was not able to modulate resistance to etoposide in HEK/R482T cell line. This suggests that mutant BCRP proteins presented altered properties for pharmacologic modulation (Table III) .
Intracellular accumulation of etoposide is reduced in BCRP-transfected cells.
The difference between the levels of resistance to etoposide shown in Table III (Fig. 3A and B) .
The [ 3 H]-etoposide uptake represented 63 (p<0.02), 40 (p<0.01) and 54% (p<0.02), respectively, in HEK/R482, HEK/ R482G and HEK/R482T, of the value measured in HEK/V cells ( Fig. 3A and B) . Moreover, the [ (Fig. 3C) .
Cell line --------------------------------------------------------------------------
In order to confirm these data, we treated the cells simultaneously with etoposide and 100 µM novobiocin. In all BCRP-transfected cell lines the intracellular concentration of [ 3 H]-etoposide has been found increased (Fig. 3A) . [ 3 H]-etoposide uptake reached 92 (p<0.05), 77 (p<0.02) and 81% (p<0.05) in HEK/R482, HEK/R482G and HEK/R482T cells, respectively, when compared to the values observed in the absence of novobiocin. Moreover, a similar effect was observed when BCRP-transfected cells were treated with 10 µM FTC (Fig.  3B ). This suggests that the resistance to etoposide is actually due to its transport by BCRP. (Fig. 4) . However, in HEK/R482, HEK/R482G and HEK/R482T cells treated with FTC, the cellular residual [ 3 H]-etoposide was increased to 73 (p<0.02), 77 (p<0.01) and 68% (p<0.01) of the initial concentration, and was significantly higher than that observed in the absence of FTC (Fig. 4) .
Discussion
The human BCRP has been shown to confer resistance to mitoxantrone, anthracyclines and camptothecins (3, 4) . In drug-selected cell lines, two different mutations leading to a transition from arginine 482 to threonine (R482T) and glycine (R482G) respectively, have been observed (9, 10) . R482T mutation confers high-level resistance to anthracyclines (21) , and cells with R482G or R482T mutation are able to efflux more efficiently rhodamine 123 (9) . Moreover, R482G mutation seems to confer relatively less resistance to camptothecins. All these data suggest that amino acid 482 has a crucial role in BCRP function and that mutation of this amino acid significantly changes substrate specificity, thus altering the drug resistance phenotype.
BCRP has been recently involved in resistance to etoposide. Moreover, when P-glycoprotein (P-gp)-and Mrp1-deficient mouse cells are selected for resistance to etoposide, amplification and overexpression of Bcrp1 emerged as the dominant resistance mechanism (8) . In order to study the role of this protein in resistance to etoposide in human, we used the embryonic HEK293 cells transfected with the wild-type BCRP (HEK/ R482) or its two mutants R482G (HEK/R482G) and R482T (HEK/R482T) (5) . As compared with HEK/V cells, all of transfected cell lines displayed resistance to mitoxantrone and transported efficiently the BCRP substrate Hoechst 33342 (Table III and data not shown). Determination of rhodamine 123 uptake confirmed that HEK/R482G and HEK/R482T cells transported efficiently this probe when compared with HEK/R482 cells (data not shown).
In our study, we have shown that wild-type BCRP, R482T and especially R482G mutant can confer significant resistance to etoposide, the HEK/R482G cells showing an IC 50 value six-fold higher than in HEK/R482 cells (Table III) . In this case, the resistance may be correlated with a decrease in the etoposide intracellular concentration (Fig. 3) . Nevertheless, HEK/R482 and HEK/R482T cells were only 5-and 8-fold resistant, respectively, to etoposide (Table III) . This suggest that R482G mutation confer to the BCRP protein a better affinity for etoposide than the mutation R482T, or a better efficiency in drug efflux, as suggested by our results (Fig. 3) .
The BCRP inhibitors FTC and novobiocin was able to significantly modulate resistance to etoposide and with a higher efficiency in the two mutants (Table III) . In the presence of FTC, cellular uptake of etoposide was significantly increased and particularly in HEK/R482 and HEK/R482G cells. Etoposide efflux measurements showed that inhibition of BCRP with FTC leads to a significant increase in intracellular concentration of etoposide in BCRP-transfected cell lines, as compared to untreated cells (Fig. 4) . Allen and co-workers have shown that Bcrp1-mediated etoposide resistance was reversed by two structurally different BCRP/ Bcrp1 inhibitors, GF120918 and Ko143 (8) . The same authors suggested that mutation at R482 was not necessary for Bcrp1-mediated resistance to etoposide because the Bcrp1 expressed in the etoposide-resistant cells was wild-type at this position (22) . Our data show clearly that R482G mutation is able to increase resistance to etoposide. Since several recent studies have demonstrated the role of BCRP expression in drug resistance in cancer (4) and given previous evidence that even low levels of drug transporters may have a substantial effect on the basal resistance to substrate drugs (23), BCRP may be taken into account as a potential contributor to resistance to etoposide. Finally, the mutation analysis at codon 482 of BCRP may be of great importance in clinical cancers treated with etoposide. Recently, only two studies have analysed the BCRP mRNA sequence on patient samples (24, 25) .
